On March 21, 2023 Artera, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, reported that it launches publicly today with $90M in funding (Press release, Artera, MAR 21, 2023, View Source [SID1234629131]). The investment comes from a syndicate of prominent tech and healthcare investors, comprised of seven institutions (Coatue, Johnson & Johnson Innovation – JJDC, Inc., Koch Disruptive Technologies, Walden Catalyst Ventures, TIME Ventures, Breyer Capital, The Factory) and 11 angel investors (Marc Benioff, Jim Breyer, Lip-Bu Tan, Chris Re, Andy Jacques, Amarjit Gill, Jeff Dean, Steve Blank, Dennis Wong, Clarence So, Michael Driscoll).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Artera’s flagship test is the ArteraAI Prostate Test, the first test to predict therapy benefit in localized prostate cancer. The investment will help distribute this test in the U.S. and internationally. The company also plans to use the funding to invest in the development of tests to support therapy personalization in other cancers.
"The American Cancer Society estimates that more than 288,000 new cases of prostate cancer will arise in 2023, with more than 34,000 deaths. AI has given clinicians and patients a powerful weapon in the fight against this disease," said Andre Esteva, co-founder and CEO of Artera. "Clinicians can now leverage Artera’s unique test to prognosticate patient outcomes and personalize treatment decisions."
"We are honored to be part of what we believe to be one of the greatest advances in prostate oncology in the last 20 years," said Marc Benioff, CEO of Salesforce.
"In the last 18 months, Artera’s AI-informed approach to personalized cancer treatment has unlocked commercial and regulatory traction well ahead of genomic competitors," said Stephen Cho, Partner at Coatue. "We are thrilled to support Artera as a pioneer in computational diagnostics for an important therapeutic area."
This announcement comes on the heels of Artera’s recently released, positive data at ASCO (Free ASCO Whitepaper) GU 2023, highlighting that the prognostic biomarker was validated across six phase III randomized trials. The study further demonstrated the ability of Artera’s multimodal artificial intelligence prognostic biomarker to help enable personalized, shared decision-making for patients and clinicians.
The ArteraAI Prostate Test is a clinically available, laboratory-developed test. For more information or to order the test please visit artera.ai.